▶︎ STRM.BIO
6 known investors
STRM.BIO develops a gene therapy delivery platform based on megakaryocyte-derived extracellular vesicles (STRM MVs) that target and deliver genetic cargoes preferentially to bone marrow and hematopoietic stem cells. The platform enables in vivo genetic medicines with an initial focus on rare hematological diseases and CAR-T therapies, supporting approaches such as gene editing, RNA therapeutics, and immune cell engineering.
Investors · 6
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2.1M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does ▶︎ STRM.BIO do?
- STRM.BIO develops a gene therapy delivery platform based on megakaryocyte-derived extracellular vesicles (STRM MVs) that target and deliver genetic cargoes preferentially to bone marrow and hematopoietic stem cells. The platform enables in vivo genetic medicines with an initial focus on rare hematological diseases and CAR-T therapies, supporting approaches such as gene editing, RNA therapeutics, and immune cell engineering.
- Who are ▶︎ STRM.BIO's investors?
- ▶︎ STRM.BIO's investors include Ascension Ventures, Breakout Labs, Breakout Ventures, Delos Capital, NYBC Ventures, KdT Ventures.